类风湿关节炎创新疗法:CAR T细胞与双特异性抗体
综述评述深度B细胞清除疗法在类风湿关节炎中的临床与转化证据,包括双特异性T细胞衔接器与CAR T细胞疗法。早期临床证据提示CD19导向T细胞衔接器与B细胞清除CAR T细胞可能诱导深度免疫重塑并在部分个体中实现持续无药缓解,但需创新试验设计与长期安全性监测。
要点
- 深度B细胞清除疗法旨在根除或重编程致病免疫记忆,而非慢性抑制炎症通路
- 早期证据提示部分RA患者可实现持续无药缓解
- 需长期安全性监测与深度免疫监测以负责任地转化至临床实践
核心结论
- 深度B细胞清除疗法挑战当前RA治疗框架,早期证据提示可能诱导深度免疫重塑与持续无药缓解。
研究设计与样本
- 综述类文章,检索并批判性评述支持深度B细胞清除疗法在RA中应用的临床与转化证据。
主要发现
- 早期临床证据提示CD19导向T细胞衔接器与B细胞清除CAR T细胞可能诱导深度免疫重塑并在部分个体中实现持续无药缓解。
关键数值与推荐
- 综述比较了深度B细胞清除疗法的机制、可行性与危害,并讨论其在整个疾病谱中的潜在定位。
临床怎么用
- 提出研究议程优先创新试验设计、深度免疫监测、组织学分析与长期安全性监测,以将深度B细胞清除策略转化至风湿病实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rheumatoid arthritis is a chronic immune-mediated inflammatory disease, and therapeutic strategies predominantly rely on continuous immunomodulation. Despite major advances with biological and targeted synthetic disease-modifying antirheumatic drugs, some patients develop persistent, objectively active inflammatory disease that remains refractory to multiple therapeutic mechanisms. Durable drug-free remission is rare, highlighting a major unmet need. Emerging deep B-cell depleting therapies, including bispecific T-cell engagers and chimeric antigen receptor (CAR) T-cell-based therapies, challenge the current treatment framework by aiming to eradicate or reprogramme pathogenic immune memory rather than chronically suppress inflammatory pathways. Early clinical evidence in rheumatoid arthritis suggests that CD19-directed T-cell engagers and B-cell depleting CAR T cells might induce profound immunological remodelling and sustained drug-free remission in some individuals. This Review critically appraises the available clinical and translational evidence supporting deep B-cell depleting therapies in rheumatoid arthritis, compares their mechanisms, feasibility, and harms, and discusses their potential positioning across the disease spectrum. Finally, this Review proposes a research agenda that prioritises innovative trial designs, deep immunomonitoring, tissue-based analyses, and long-term safety surveillance to responsibly translate deep B-cell depleting strategies into rheumatology practice.
引用
- Avouac J, Jouret M, Bitoun S, et al. Innovative therapies in rheumatoid arthritis: CAR T cells and bispecific antibodies. Lancet Rheumatol. 2026. PMID: 42896926. doi:10.1016/S2665-9913(26)00184-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。